Home › Athersys' MultiStem(R) Stem Cell Therapy Receives Orphan Drug Designation In Europe For Prevention Of Graft-Versus-Host Disease
 

Keywords :   


Athersys' MultiStem(R) Stem Cell Therapy Receives Orphan Drug Designation In Europe For Prevention Of Graft-Versus-Host Disease

2013-12-30 06:10:10| drugdiscoveryonline Home Page

Athersys, Inc. (Nasdaq:ATHX) announced today that the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) has issued a positive opinion (EMA/OD/146/13) for the Company's allogeneic, multipotent adult progenitor cell, or MultiStem® therapy, for the prevention of graft-versus-host disease (GvHD)

Tags: europe cell drug disease

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
07.11Lawsuit over FDA's regulatory approval process for carbadox dismissed
07.11Hurricane Rafael Graphics
07.11Hurricane Rafael Forecast Discussion Number 16
07.11Hurricane Rafael Wind Speed Probabilities Number 16
07.11Hurricane Rafael Forecast Advisory Number 16
07.11Hurricane Rafael Public Advisory Number 16
07.11Summary for Hurricane Rafael (AT3/AL182024)
07.11Tropical Depression Fourteen-E Graphics
More »